Pricing
  1. JP-listed companies
  3. Cash flow

(219A) Cash flow

Market cap
¥39.8B
P/E ratio
-18.7x
Heartseed develops regenerative heart muscle therapies using iPS cell-derived cardiac spheres to treat severe heart failure patients through medical institutions worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Income statementBalance sheetCash flowOther
2022/102023/102024/102025/12
Depreciation & amortization084253
Cash from operations -1,922-798-1,3431,081
Capital expenditures--328-14-29
Cash from investing -1-426-6773
Cash from financing -221,8482,119376
Free cash flow-
FCF margin (%)-
AI Chat